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Abstract
A small molecule (1835F03) that inhibits Staphylococcus aureus wall teichoic acid biosynthesis, a
proposed antibiotic target, has been discovered. Rapid, parallel, solution-phase synthesis was
employed to generate a focused library of analogs, providing detailed information about structure-
activity relationships and leading to the identification of targocil, a potent antibiotic.
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More people now die from hospital-acquired methicillin-resistant S. aureus infections in the
United States than from HIV/AIDs.1 Until recently, vancomycin was known as the “last line
of defense” against these infections, but high-level vancomycin resistance has now begun to
appear in S. aureus.2–4 Although two new classes of antibiotics to treat S. aureus infections
have been introduced in the past decade, clinical resistance to each has already appeared and
can be expected to spread.5–7 For these reasons, a deep pipeline of novel antibiotics is required
to combat MRSA infections.8
One suggested but as yet unexploited antibiotic target in S. aureus is wall teichoic acid (WTA)
biosynthesis.9, 10 WTAs are anionic, phosphate-rich, carbohydrate-based polymers that are
synthesized on a lipid carrier inside the bacterial cell before being transported to the cell surface
where they are covalently linked to peptidoglycan.11 Their biological functions are diverse,
ranging from cation homeostasis to critical roles in host colonization.12 They are proposed
virulence factors since deleting the biosynthetic pathway by knocking out the first gene
(tarO) prevents infection. The downstream enzymes in the this pathway are potential antibiotic
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targets since initiating flux into the biosynthetic pathway without completing it is deleterious
to bacterial viability.13
We have discovered the first small molecule that specifically inhibits WTA biosynthesis using
a cell-based, pathway-specific high-throughput screen that reports only on the antibiotic targets
in the pathway. From a screen of 55,000 compounds, we identified 1835F03 (1) as a WTA-
active antibiotic.14 Compound 1 has good antibiotic activity (low μM) against all S. aureus
strains tested, including both hospital- and community-acquired MRSA isolates. We identified
the target of 1 as TarG, the transmembrane component of the two component ABC transporter
that exports WTAs from the cytoplasm to the external surface of the bacterial membrane where
they are attached to peptidoglycan (Figure 1).14 Two other compounds (1856A19 and
1856K21) that share a similar core with 1 were also identified as confirmed “hits” from the
screen, but their potencies were lower (Figure 2). Moreover, commercial analogs of this class
of inhibitors (1856A19 and 1856K21) appeared to have diminished target specificity relative
to 1 since they showed partial growth inhibitory activity against the ΔtarO mutant strain (see
Supplementary Table 1). Therefore we focused on 1 as a lead for optimization.
The commercially available analogs of compound 1 had limited structural variations and all
lacked activity (see Supplementary Figures 1 and 2). Therefore, we prepared a focused library
of compound 1 analogs in order to identify sites on the scaffold that could be altered to improve
potency without sacrificing selectivity for the target. The studies reported below provide key
information about where this class of compounds is amenable to modification and have led to
the identification of an analog that is ten times more potent than 1 and is non-toxic in mice at
doses of 75 mg/kg.
Based on the structure of 1 (1835F03), libraries of compounds with varying core substitution
and side chains were prepared. The triazoloquinazoline core was synthesized following
previously published methods (Scheme 1).15 The 2-azidobenzoic acid or ester, prepared from
the corresponding anthranilic acid derivative, was heated with an arylsulfonylacetonitrile in
the presence of base to furnish the triazoloquinazolone framework in one step. This reaction
is believed to proceed via 1,3-dipolar cycloaddition of the azide to the enolate form of the
nitrile, followed by cyclocondensation of the resulting aminotriazole. The yields of the
triazoloquinazolones varied depending on the substituents on the azidobenzoic acid. While the
cyclization proceeded smoothly with electron-deficient ring systems, such as chloro- or nitro-
substituted azidobenzoic acids, yields were low to moderate with electron-rich substrates.
However, use of potassium carbonate in place of sodium methoxide (as previously published)
resulted in moderate improvement. Chlorination of the resulting quinazolone using phosphorus
oxychloride in the presence of tetramethylammonium chloride afforded the chloroquinazoline,
which was converted in a straightforward manner to the corresponding aminoquinazoline
derivatives. Whenever possible, the synthesis was carried out in a parallel format where the
reactions were conducted in vials and the products were worked up by parallel solid phase
extraction (SPE) using strong cation exchange (SCX) cartridges. Interestingly, attempts to
remove the methyl ethers of 38 (in order to install solubilizing functional groups) utilizing
boron tribromide caused ring opening of the triazole with concomitant loss of nitrogen, yielding
inactive compounds (see SI for details).
All compounds were tested for antibacterial activity against a common laboratory strain of S.
aureus, RN4220, and against the isogenic RN4220 ΔtarO strain, which lacks the first gene in
the biosynthetic pathway and is thus not susceptible to WTA inhibitors. This latter strain allows
for assessment of compound specificity since any toxic effects against it must be due to
mechanisms other than WTA inhibition. The minimum inhibitory concentrations (MIC) of all
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compounds are reported against both strains in Tables 1 and 2 and Figure 3. Active compounds
were subsequently tested against clinical S. aureus isolates (see Table 3).
The first analog library was designed to investigate the positions, sizes and electronics of the
A-ring substituents. Commercial starting materials were chosen to probe the amenability of
this area of the molecule to derivatization. The chloro group was placed at all possible locations
on the A-ring (2–4), but activity was lost when this functionality was displayed anywhere other
than C2. Therefore, we sought to optimize the substituent at this position. Modest changes at
the C2 position (i.e., F, Me, Br, NO2, CN; 5–9) gave compounds with lower activity than the
parent C2-chloro compound (1). Replacement of the chloro group with a methyl (6), bromo
(7), or methoxy (10) substituent was tolerated, while a fluoro (5), nitro (8), or cyano (9) group
abolished activity. From these data, it appears that size rather than electronics is the determining
factor for activity. Likewise, substituents displayed at the C3 position resulted in inactive
compounds 11–14. Surprisingly, however, 2,3-dimethoxy substitution on the A-ring yielded
a potent compound (15). Since both the mono-methoxy derivatives (10 and 14) are less active
than the parent compound 1, the effects of changing these positions are not additive. The
benzodioxane analog (16) was also prepared, but found to be inactive, suggesting that some
flexibility of the substituents may be important. The 2,3-dimethoxy substitution on the A-ring
was incorporated into additional analogs in anticipation that it would give improved
physicochemical properties (e.g., cLogP) compared to the C2 chloro.
With the A-ring substitution fixed, variations to the amine side chains of the B-ring (Figure 3)
were examined, including several primary and secondary amines (17–36), but few variants
matched the potency of the parent diethylamine side chain (15). From the MIC data, it was
clear that neither a hydrophilic moiety (e.g., 21, 27, 28, 30) nor a larger, hydrophobic group
(e.g., 19, 20, 33–36) was tolerated. Only the acyclic secondary amines of small alkyl groups
imparted reasonable antibacterial activity (i.e., 24–26). It is surmised that this residue binds to
a hydrophobic pocket that is of limited size and depth so that it can only accommodate
C2~C4 alkyl groups at the nitrogen atom. Therefore, additional optimization was pursued
retaining the diethylamine group on the B-ring.
Finally, we explored changes to the D-ring. Compounds 37 and 38 were made, which contain
a para-methyl and para-chloro substituent on the D-ring, respectively. The 4-
chlorophenylsulfone analog (38) exhibited the highest antibacterial activity of all compounds
made, with an MIC of 0.3 μM against the S. aureus lab strain (RN4220), which shows that
modifying the D-ring can have beneficial effects. A broader exploration of D-ring substitutions
was hampered by the lack of commercially available arylsulfonyl-acetonitriles. However, since
the biological activity of 38 is sufficient (see below) we did not pursue other synthetic
approaches to make D-ring analogs. Efforts to combine the best features from each sublibrary
(namely, the 2,3-di-OMe on the A-ring, ethylisopropylamine on the B-ring and para-chloro
on the D-ring) generated 39. However, its activity was not improved over 38.
The original inhibitor 1 and two representative active analogs (15 and 38) were tested against
four additional S. aureus strains (Table 3). All showed growth inhibitory activities against both
methicillin-sensitive (RN6390 and Newman) and methicillin-resistant (MW2 and COL) S.
aureus strains, with 38 consistently showing the most potent activity.
Compound 38, which we have named targocil, has a bacteriostatic mechanism of action like
the original compound (1). Its activity depends on flux into the WTA biosynthetic pathway
since the ΔtarO mutant is not susceptible (see Table 2). Several lines of evidence indicate that
targocil (38) inhibits the same target in the WTA biosynthetic pathway as 1. For example,
targocil (38) shows cross-resistance with mutants selected against 1. Some of these
characterized mutant strains contain point mutations in tarG; others contain mutations in
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tarO that abolish the expression of WTAs, making the TarG transporter nonessential.
Furthermore, resistant mutations selected against targocil (38) itself map to tarG as well as
tarO.
One surprising finding was that the measured mutational frequency of S. aureus Newman for
targocil (38) was found to be 7 × 10−7 per cell division, which is at least 10-fold lower than
the frequency estimated for compound 1.14, 16 The measured frequency of resistance to targocil
(38) in vitro is still higher than is typically desirable, but many of the resistant mutants are
pathway nulls. Since these mutants are avirulent, they are not expected to contribute to
resistance in vivo, and the compound is thus highly promising.9, 10
The acute toxicity of targocil (38) is acceptable. Doses of 75 mg/kg administered via tail vein
injection (see SI for details) caused no adverse effects in mice after 24 h. Although the MIC
of tarogicl (38) shifts by a factor of eight in the presence of 50% fetal bovine serum, its tolerated
dose in mice is greater than 100-fold the serum MIC.
In conclusion, a structure-activity relationship study of the WTA inhibitor 1 identified positions
that are tolerant of substitution and led to the discovery of an analog (targocil, 38) that is ten-
fold more potent than the original screening hit while also having a ten-fold reduced mutational
frequency. Targocil (38) is active against methicillin-sensitive and resistant clinical strains,
and analysis of resistant mutants shows that it inhibits the same target as 1 (TarG). Its properties
suggest that it is a candidate for proof of concept studies to address whether inhibiting WTA
biosynthesis is a promising strategy for treating bacterial infections in vivo.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Poly(ribitol-phosphate) wall teichoic acids are constructed on a bactoprenol carrier lipid
(C55~P; partial structures shown here) embedded in the cytoplasmic membrane in S. aureus.
TarGH is the ABC transporter that exports WTAs and is the target of the class of small molecule
antibiotics described here. X and Y denote tailoring modifications of the WTA polymer (e.g.,
alanylation and glycosylation).
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Chemical structures of the most active hits discovered in our high-throughput screen, with
“common” core structures shown in bold.
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SAR of the B-ring amine side chains. MICs are given as the lowest concentration of compound
(tested) that gave >90% growth inhibition in wildtype S. aureus RN4220. MICs are represented
as >100 μM if the derivative gave between 31 and 89% growth inhibition at the highest
concentration tested (100 μM). Compounds 33 and 36 showed greater than 70% growth
inhibition in the ΔtarO mutant at 100 μM, whereas the remaining derivatives gave less than
30% growth inhibition (data not shown).
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Synthesis of triazoloquinazoline analogs.
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Table 1
A-ring derivatives and their corresponding minimum inhibitory concentrations (MIC) against Staphylococcus
aureus RN4220.
Compds R Wildtype S. aureus MIC (μM) ΔtarO S. aureus MIC (μM)
1 2-Cl 3.6 na a
2 1-Cl na na
3 3-Cl na na
4 4-Cl na na
5 2-F >100 na
6 2-Me 25 na
7 2-Br 12.5 >100
8 2-NO2 >100 na
9 2-CN na na
10 2-OMe 25 na
11 3-Me na na
12 3-Br >100 100
13 3-NO2 100 50
14 3-OMe >100 >100
15 2,3-di-OMe 1.8 na
16 2,3-OCH2CH2O- na na
a
na (not active) indicates <30% growth inhibition at 100 μM. MICs are represented as >100 μM if the compound gave between 31 and 89% growth
inhibition at the highest concentration tested (100 μM).
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Table 2
D-ring substitutions can enhance biological activity. The lack of activity against the ΔtarO strain indicates
specificity for the WTA biosynthetic pathway.
Compds R1 R2 Wildtype S. aureus MIC (μM) ΔtarO S. aureus MIC (μM)
15 H H 1.8 na a
37 H CH3 2.5 na
38 H Cl 0.3 na
39 CH3 Cl 2.5 na
a
na [not active] indicates <30% growth inhibition at 100 μM.
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Table 3
MICs of the original inhibitor and two analogs against several S. aureus strains.
Compds RN6390 MIC (μM) a Newman MIC (μM) COL MIC (μM) MW2 MIC (μM)
1 6.3 12.5 6.3 6.3
15 3.1 3.1 3.1 3.1
38 0.3 0.3 0.6 0.6
a
MICs are given as the lowest concentration of compound (tested) that gave >85% growth inhibition in each strain.
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